TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda^® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA)

Read more at prnewswire.com